Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

4.19 -15.86

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.17

Max

4.28

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	2.2M -35M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+76.07% upside

Dividendes
By Acuity
Prochains Résultats	11 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	36M 331M
Ouverture précédente	20.05
Clôture précédente	4.19

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 août 2026, 23:51 UTC

U.S. Labor Market Contraction Fuels Stock Market Rally and Eases Fed Rate Hike Expectations

8 août 2026, 23:51 UTC

U.S. equity markets surge to record highs as July job data signals potential pause in Federal Reserve interest rate hikes, while European stocks also reach all-time highs amid mixed economic signals.

8 août 2026, 23:51 UTC

U.S. equity markets surge to record highs as disappointing July employment data shifts investor sentiment towards a potential pause in Federal Reserve interest rate hikes.

8 août 2026, 23:51 UTC

U.S. equity markets surge as disappointing July jobs data lowers Fed rate hike expectations, with S&P500 hitting record high.

8 août 2026, 23:51 UTC

US Producer Price Inflation Expected to Rise 0.1% in July Amid Labor Market Concerns and Fed Rate Speculations

8 août 2026, 23:51 UTC

Correlated Moves

Macro News

Bitcoin trades higher as a surprising jobs report fuels speculation of interest rate cuts, potentially benefiting cryptocurrencies. Ethereum also sees a slight price increase.

8 août 2026, 23:41 UTC

Core PPI Release on August 13, 2026, Expected to Show Moderate Inflation Increase Amid Mixed Labor Market Signals and Cautious Investor Sentiment.

8 août 2026, 23:31 UTC

BoJ's Upcoming Summary of Opinions on August 9, 2026, May Signal Cautious Monetary Policy Amidst Mixed Market Sentiment and Global Rate Hike Discussions.

8 août 2026, 23:21 UTC

Core Inflation Rate Expected at 2.5% Amid Mixed Economic Data and Job Losses, Influencing Fed's Interest Rate Decisions

8 août 2026, 23:21 UTC

Core Inflation Rate Release on August 12, 2026 Expected to Show +0.2% Increase Amid Mixed Economic Signals and Job Market Concerns

8 août 2026, 23:21 UTC

Investors Brace for July CPI Release Amid Mixed Employment Reports and Inflation Concerns Impacting Fed Policy Decisions

8 août 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.1% in July Amid Mixed Economic Signals and Labor Market Concerns

8 août 2026, 23:21 UTC

US CPI YoY Inflation Rate Expected at 3.4% Amid Mixed Economic Signals and Job Losses, Influencing Fed's Interest Rate Decisions

8 août 2026, 23:21 UTC

Investors Brace for Volatility Ahead of August CPI Release Amid Mixed Economic Signals and Fed Rate Speculation

8 août 2026, 23:11 UTC

Brazil's Retail Sales Report on August 13 Expected to Reveal Consumer Spending Trends Amid Economic Uncertainties.

8 août 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit Year-High of 6.81% Amid Weak Job Growth and Fed Rate Speculation

8 août 2026, 22:41 UTC

Cardano is trading lower today, continuing a downward trend since Friday. The asset remains above its 20-day moving average and near its one-month range high.

8 août 2026, 22:31 UTC

Brazil's Inflation Rate MoM Release on August 11, 2026, Sparks Caution Among Analysts Amid Global Economic Uncertainties.

8 août 2026, 22:31 UTC

Brazil's Inflation Rate Release on August 11, 2026 Expected to Reflect Moderate Trends Amid Global Economic Concerns.

8 août 2026, 22:11 UTC

UK Housing Market Faces Caution Ahead of RICS House Price Balance Release Amid Stagnant Prices and Economic Uncertainty

8 août 2026, 21:51 UTC

Japan's Current Account Surplus Forecasted at JPY 1,512 Billion Amid Forex Interventions and Cautious Market Sentiment Ahead of August Release.

8 août 2026, 21:41 UTC

South Korea's unemployment rate expected to hold steady at 2.7% amid global economic uncertainties, with market sentiment cautiously optimistic ahead of August release.

8 août 2026, 21:31 UTC

UK Retail Sales Monitor YoY for July 2026 Expected to Rise 1.5% Amid Mixed Sentiment and Economic Pressures

8 août 2026, 21:21 UTC

India's July 2026 Inflation Rate Release Expected to Show Stability at 4.54% Amid Geopolitical Tensions and Food Price Pressures

8 août 2026, 21:21 UTC

Brazil's Central Bank to announce interest rate decisions amid global economic uncertainties on August 10, 2026.

8 août 2026, 20:31 UTC

Euro Area's Q2 Employment Change Data Release on August 14 Sparks Cautious Optimism Amid Rising Unemployment and Mixed Economic Signals.

8 août 2026, 20:31 UTC

Euro Area Expected to Report €2.2 Billion Trade Deficit Amid Mixed Economic Signals and Rising Energy Costs

8 août 2026, 20:31 UTC

China's Q2 2026 Current Account Data Release Expected to Show Continued Surplus Growth Amidst Global Economic Pressures

8 août 2026, 20:11 UTC

Eurozone Industrial Production MoM data for June 2026 expected to show flat growth amid concerns over declining output and geopolitical tensions.

8 août 2026, 20:01 UTC

South Africa's Q2 Unemployment Rate Set for Release Amidst Rising Global Job Concerns, Following Alarming 32.7% in Q1

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

76.07% hausse

Prévisions sur 12 Mois

Moyen 7.43 USD 76.07%

Haut 11 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.